Improved risk-adjusted survival for melanoma brain metastases in the era of checkpoint blockade immunotherapies: results from a national cohort

JB Iorgulescu, M Harary, CK Zogg, KL Ligon… - Cancer immunology …, 2018 - AACR
The successes of checkpoint blockade immunotherapy (CBI) and BRAFV600-targeted
therapy trials have generated substantial promise for revolutionizing the management of …
被引用次数：72 相关文章

Improved Risk-Adjusted Survival for Melanoma Brain Metastases in the Era of Checkpoint Blockade Immunotherapies: Results from a National Cohort

JB Iorgulescu, M Harary, CK Zogg… - Cancer …, 2018 - pubmed.ncbi.nlm.nih.gov
The successes of checkpoint blockade immunotherapy (CBI) and BRAF V600-targeted
therapy trials have generated substantial promise for revolutionizing the management of …

Improved Risk-Adjusted Survival for Melanoma Brain Metastases in the Era of Checkpoint Blockade Immunotherapies: Results from a National Cohort.

JB Iorgulescu, M Harary, CK Zogg… - Cancer Immunology …, 2018 - europepmc.org
The successes of checkpoint blockade immunotherapy (CBI) and BRAF V600-targeted
therapy trials have generated substantial promise for revolutionizing the management of …
[HTML] nih.gov

[HTML][HTML] Improved Risk-Adjusted Survival for Melanoma Brain Metastases in the Era of Checkpoint Blockade Immunotherapies: Results from a National Cohort

JB Iorgulescu, M Harary, CK Zogg… - Cancer immunology …, 2018 - ncbi.nlm.nih.gov
The successes of checkpoint blockade immunotherapy (CBI) and BRAF V600-targeted
therapy trials have generated substantial promise for revolutionizing the management of …
[PDF] researchgate.net

[PDF][PDF] Improved Risk-Adjusted Survival for Melanoma Brain Metastases in the Era of Checkpoint Blockade Immunotherapies: Results from a National Cohort

JB Iorgulescu, M Harary, CK Zogg, KL Ligon… - Cancer, 2018 - researchgate.net
The successes of checkpoint blockade immunotherapy (CBI) and BRAFV600-targeted
therapy trials have generated substantial promise for revolutionizing the management of …

Improved risk-adjusted survival for melanoma brain metastases in the era of checkpoint blockade immunotherapies: Results from a national cohort

JB Iorgulescu, M Harary… - Cancer …, 2018 - mdanderson.elsevierpure.com
The successes of checkpoint blockade immunotherapy (CBI) and BRAF V600-targeted
therapy trials have generated substantial promise for revolutionizing the management of …
[PDF] researchgate.net

[PDF][PDF] Improved Risk-Adjusted Survival for Melanoma Brain Metastases in the Era of Checkpoint Blockade Immunotherapies: Results from a National Cohort

JB Iorgulescu, M Harary, CK Zogg, KL Ligon… - Cancer, 2018 - researchgate.net
The successes of checkpoint blockade immunotherapy (CBI) and BRAFV600-targeted
therapy trials have generated substantial promise for revolutionizing the management of …